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Summary
Objective: Overproduction of nitric oxide (NO) and prostaglandin E2 (PGE2) plays an important role in the pathogenesis of osteoarthritis (OA).
In the present study, we determined the effect of trichostatin A (TSA) and butyric acid (BA), two histone deacetylase (HDAC) inhibitors, on NO
and PGE2 synthesis, inducible NO synthase (iNOS) and cyclooxygenase (COX)-2 expression, and nuclear factor (NF)-kB DNA-binding ac-
tivity, in interleukin-1b (IL-1)-stimulated human OA chondrocytes, and on IL-1-induced proteoglycan degradation in cartilage explants.
Methods: Chondrocytes were stimulated with IL-1 in the absence or presence of increasing concentrations of TSA or BA. The production of
NO and PGE2 was evaluated using Griess reagent and an enzyme immunoassay, respectively. The expression of iNOS and COX-2 proteins
and mRNAs was evaluated using Western blotting and real-time reverse transcriptase-polymerase chain reaction (RT-PCR), respectively.
Proteoglycan degradation was measured with dimethymethylene blue assay. Electrophoretic mobility shift assay (EMSA) was utilized to an-
alyze the DNA-binding activity of NF-kB.
Results: HDAC inhibition with TSA or BA resulted in a dose-dependent inhibition of IL-1-induced NO and PGE2 production. IL-17- and tumor
necrosis factor-a (TNF-a)-induced NO and PGE2 production was also inhibited by TSA and BA. This inhibition correlated with the suppression
of iNOS and COX-2 protein and mRNA expression. TSA and BA also prevented IL-1-induced proteoglycan release from cartilage explants.
Finally, we demonstrate that the DNA-binding activity of NF-kB, was induced by IL-1, but was not affected by treatment with HDAC inhibitors.
Conclusions: These data indicate that HDAC inhibitors suppressed IL-1-induced NO and PGE2 synthesis, iNOS and COX-2 expression, as
well as proteoglycan degradation. The suppressive effect of HDAC inhibitors is not due to impaired DNA-binding activity of NF-kB. These
ﬁndings also suggest that HDAC inhibitors may be of potential therapeutic value in the treatment of OA.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common joint disorder and
a leading cause of disability among the elderly population.
It is characterized by progressive degenerative structural
changes in articular cartilage, leading to loss of joint func-
tion. It is also characterized by excessive production of sev-
eral inﬂammatory mediators1e3. Among these mediators,
the pro-inﬂammatory cytokine interleukin-1b (IL-1) plays*Address correspondence and reprint requests to: Dr Hassan
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1267a pivotal role in the pathophysiology of OA. It induces a cas-
cade of inﬂammatory and catabolic events in chondrocytes
including the synthesis of prostaglandin E2 (PGE2) and ni-
tric oxide (NO). IL-1 also alters chondrocyte anabolism by
suppressing the synthesis of proteoglycan and collagen
and by enhancing the production of matrix metalloprotei-
nases (MMPs)1e3.
NO is synthesized from L-arginine by a family of NO syn-
thases (NOSs) of which three isoforms have been identi-
ﬁed. Neuronal NOS (nNOS) and endothelial NOS (eNOS)
are constitutively expressed, while the inducible NOS
(iNOS) is expressed following stimulation with a variety of
inﬂammatory agents such as endotoxins or cytokines4.
NO promotes inﬂammation by enhancing the production
of inﬂammatory cytokines5 and PGE2
6 and by reducing
1268 N. Chabane et al.: HDAC inhibitors suppress IL-1b-induced NO and PGE2 productionthe synthesis of endogenous IL-1 receptor antagonist (IL-1
Ra)7. NO is also considered a potent catabolic agent in OA
since it inhibits collagen and proteoglycan synthesis8,9,
stimulates the production and activation of MMPs10 and in-
duces chondrocyte apoptosis11. Accordingly, the in vivo se-
lective inhibition of iNOS in an experimental model of OA
reduces the joint structural changes and the expression of
several inﬂammatory and catabolic factors, including IL-1
and MMP-112.
The biosynthesis of PGE2 from arachidonic acid (AA) in-
volves multiple enzymes including, cyclooxygenases
(COXs). Two isoforms of COX have been identiﬁed: COX-
1 is constitutively expressed in most tissues, whereas
COX-2 is induced by various stimuli such as endotoxins,
growth factors and pro-inﬂammatory cytokines13. PGE2 is
the most abundant prostanoid in arthritic joint and one of
the major catabolic mediators involved in cartilage resorp-
tion. PGE2 elicits cartilage resorption by enhancing the ac-
tivation and production of MMPs and the degradation of
cartilage matrix components14,15 and by promoting chon-
drocyte apoptosis16. In addition PGE2 mediates pain re-
sponses and potentiates the effects of other inﬂammatory
mediators13.
Acetylation and deacetylation of nucleosomal histones
play an important role in the regulation of gene expres-
sion17,18. The histone acetylation status is controlled by
the opposing actions of two classes of enzymes: histone
acetyl transferases (HATs) and histone deacetylases
(HDACs). Acetylation of histones loosens nucleosomal
structures, thereby promoting gene transcription. In con-
trast, deacetylation of histones stabilizes nucleosomal
structures and represses gene transcription17,18. However,
emerging evidence indicates that gene regulation by acety-
lation/deacetylation is more dynamic and complex, and that
HATs can act as repressors and HDAC as activators of
transcription. Indeed, global analysis of gene expression
has shown that inhibition of HDAC activity results both in in-
duction and repression of gene expression19e24.
In recent years, signiﬁcant interest has emerged in the
inhibition of HDAC activity as a possible anti-cancer treat-
ment. HDAC inhibitors induce growth arrest, differentiation
and apoptosis of cancer cells in vitro and reduce the
growth of experimental tumors in vivo25,26. Presently, sev-
eral HDAC inhibitors are in clinical trials for the treatment
of solid and hematological tumors27,28. In addition to their
anti-cancer effects, recent studies have demonstrated that
HDAC inhibitors modulate inﬂammatory responses. For
instance, HDAC inhibitors reduce the production of IL-1,
tumor necrosis factor-a (TNF-a), and interferon-g (IFN-g)
in lipopolysaccharide (LPS)-stimulated human peripheral
blood mononuclear cells29,30. Likewise, HDAC inhibitors
prevent LPS-induced production of TNF-a, IL-6 and reac-
tive oxygen species in neuroglia cultures, and primary mi-
croglia31e33. HDAC inhibitors have also been reported to
suppress IL-12 production in dendritic cells and macro-
phages34. However, it is currently unknown whether
HDAC inhibitors regulate inﬂammatory responses in artic-
ular chondrocytes.
Since excessive production of the inﬂammatory media-
tors NO and PGE2 plays an important role in the patho-
genesis of OA, we assessed the effect of two HDAC
inhibitors, trichostatin A (TSA) and butyric acid (BA), on
the production of NO and PGE2 in primary cultured hu-
man chondrocytes stimulated with IL-1. We additionally
analyzed the expression of iNOS and COX-2 as well as
the binding activity of transcription factor nuclear factor-
kB (NF-kB).Materials and methodsREAGENTSRecombinant human (rh) IL-1b was obtained from Genzyme (Cambridge,
MA, USA), rhTNF-a and rhIL-17 were from R&D Systems (Minneapolis, MN,
USA). TSA and BA were from SigmaeAldrich Canada (Oakville, ON, Canada).
Dulbecco’s modiﬁed Eagle’s medium (DMEM), penicillin and streptomycin,
fetal calf serum (FCS), and TRIzol reagent were from Invitrogen (Burlington,
ON, Canada). All other chemicals were purchased from either Sigmae
Aldrich Canada or Bio-Rad (Mississauga, ON, Canada).SPECIMEN SELECTION AND CHONDROCYTE CULTUREHuman normal cartilage (from femoral condyles) was obtained at nec-
ropsy, within 12 h of death, from donors with no history of arthritic disease
(n¼ 7, mean SD age: 54 16 years). To ensure that only normal tissue
was used, cartilage specimens were thoroughly examined both macroscop-
ically and microscopically. Only those with no alterations were further pro-
cessed. Human OA cartilage samples from femoral condyles and tibial
plateaus were obtained from OA patients undergoing total knee replacement
(n¼ 47, meanSD age: 66 12 years). All OA patients were diagnosed ac-
cording to the criteria developed by the American College of Rheumatology
Diagnostic Subcommittee for OA35. At the time of surgery, the patients had
symptomatic disease requiring medical treatment in the form of non-steroidal
anti-inﬂammatory drugs (NSAIDs) or selective COX-2 inhibitors. Patients
who had received intra-articular injections of steroids were excluded. The
Clinical Research Ethics Committee of Notre-Dame Hospital approved the
study protocol and the use of human articular tissues.
Chondrocytes were released from cartilage by sequential enzymatic di-
gestion as previously described36. In brief, this consisted of 2 mg/ml pronase
for 1 h followed by 1 mg/ml collagenase (type IV; SigmaeAldrich) for 6 h at
37C in DMEM and antibiotics (100 U/ml penicillin and 100 mg/ml streptomy-
cin). The digested tissue was brieﬂy centrifuged and the pellet was washed.
The isolated chondrocytes were seeded at high density in tissue culture
ﬂasks and cultured in DMEM supplemented with 10% heat-inactivated
FCS. At conﬂuence, the chondrocytes were detached, seeded at high den-
sity, and allowed to grow in DMEM, supplemented as above. The culture me-
dium was changed every second day, and 24 h before the experiment the
cells were incubated in fresh medium containing 0.5% FCS. Only ﬁrst pas-
saged chondrocytes were used.NO AND PGE2 DETERMINATIONSThe nitrite levels, used as an indicator of NO production, were determined
using the Griess assay as previously described36. The levels of PGE2 were
determined using a PGE2 enzyme immunoassay from Cayman Chemical
(Ann Arbor, MI, USA). The detection limit and sensitivity was 9 pg/ml. All as-
says were performed in duplicate.WESTERN BLOT ANALYSISChondrocytes were lysed in ice-cold lysis buffer (50 mM TriseHCl, pH
7.4, 150 mM NaCl, 2 mM EDTA, 1 mM phenylmethansulfonylﬂuorid
(PMSF), 10 mg/ml each of aprotinin, leupeptin, and pepstatin, 1% NP-40,
1 mM Na3VO4, and 1 mM NaF). Lysates were sonicated on ice and centri-
fuged at 12,000 rpm for 15 min. The protein concentration of the supernatant
was determined using the bicinchoninic acid method (Pierce, Rockford, IL,
USA). Twenty microgram of total cell lysate was subjected to SDS-poly-
acrylamide gel electrophoresis and electrotransferred to a nitrocellulose
membrane (Bio-Rad). After blocking in 20 mM TriseHCl pH 7.5 containing
150 mM NaCl, 0.1% Tween 20, and 5% (w/v) non-fat dry milk, blots were
incubated overnight at 4C with the primary antibody and washed with
a Tris buffer [Tris-buffered saline (TBS) pH 7.5, with 0.1% Tween 20]. The
blots were then incubated with horseradish peroxidase-conjugated second-
ary antibody (Pierce), washed again, incubated with SuperSignal Ultra
Chemiluminescent reagent (Pierce), and exposed to Kodak X-Omat ﬁlm
(Eastman Kodak Ltd, Rochester, NY, USA).RNA EXTRACTION AND REVERSE
TRANSCRIPTASE-POLYMERASE CHAIN
REACTION (RT-PCR)Total RNA from stimulated chondrocytes was isolated using the TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions. To remove
contaminating DNA, isolated RNA was treated with RNase-free DNase I
(Ambion, Austin, TX, USA). The RNA was quantitated using the RiboGreen
RNA quantitation kit (Molecular Probes, Eugene, OR, USA), dissolved in di-
ethylpyrocarbonate (DEPC)-treated-H2O and stored at 80C until use. One
microgram of total RNA was reverse-transcribed using Moloney Murine Leu-
kemia Virus reverse transcriptase (Fermentas, Burlington, ON, Canada) as
1269Osteoarthritis and Cartilage Vol. 16, No. 10detailed in the manufacturer’s guidelines. One ﬁftieth of the reverse transcrip-
tase reaction was analyzed by real-time PCR as described below. The fol-
lowing primers were used: iNOS, sense 50-ACATTGATGAGAAGC
TGTCCCAC-30 and antisense 50-CAAAGGCTGTGAGTCCTGCAC-30;
COX-2, sense 50-TGTGTTGACATCCAGATCAC-30 and antisense 50-ACAT
CATGTTTGAGCCCTGG-30; and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), sense 50-CAGAACATCATCCCTGCCTCT-30 and antisense
50-GCTTGACAAAGTGGTCGTTGAG-30.REAL-TIME PCRReal-time PCR analysis was performed in a total volume of 50 ml contain-
ing template DNA, 200 nM of sense and antisense primers, 25 ml of SYBR
Green master mix (QIAGEN, Mississauga, ON, Canada) and uracil-N-glyco-
sylase (UNG, 0.5 Unit, Epicentre Technologies, Madison, WI, USA). After in-
cubation at 50C for 2 min (UNG reaction), and at 95C for 10 min (UNG
inactivation and activation of the AmpliTaq Gold enzyme), the mixtures
were subjected to 40 ampliﬁcation cycles (15 s at 95C for denaturation
and 1 min for annealing and extension at 60C). Incorporation of SYBR
Green dye into PCR products was monitored in real-time using a GeneAmp
5700 Sequence detection system (Applied Biosystems, Foster City, CA,
USA) allowing determination of the threshold cycle (CT) at which exponential
ampliﬁcation of PCR products begins. After PCR, dissociation curves were
generated with one peak, indicating the speciﬁcity of the ampliﬁcation. A
threshold cycle (CT value) was obtained from each ampliﬁcation curve using
the software provided by the manufacturer (Applied Biosystems).
Relative mRNA expression in chondrocytes was determined using the
DDCT method, as detailed in the manufacturer’s guidelines (Applied Biosys-
tems). A DCT value was ﬁrst calculated by subtracting the CT value for the
housekeeping gene GAPDH from the CT value for each sample. A DDCT
value was then calculated by subtracting the DCT value of the control (unsti-
mulated cells) from the DCT value of each treatment. Fold changes com-
pared with the control were then determined by raising two to the DDCT
power. Each PCR reaction generated only the expected speciﬁc amplicon
as shown by the melting-temperature proﬁles of the ﬁnal product and by
gel electrophoresis of test PCR reactions. Each PCR was performed in trip-
licate on two separate occasions for each independent experiment.PROTEOGLYCAN RELEASECartilage proteoglycan degradation was assessed by measuring sulfated
glycosaminoglycan (GAG) released into culture media using dimethyl meth-
ylene blue (DMMB) with chondroitin sulfate as a standard37. Results are ex-
pressed as mg of GAG released/mg cartilage.NUCLEAR EXTRACT PREPARATION AND ELECTROPHORETIC
MOBILITY SHIFT ASSAY (EMSA)Nuclear extracts were prepared as previously described38. Brieﬂy, chon-
drocytes were washed in ice-cold phosphate buffered saline (PBS) and
gently scraped in ice-cold hypotonic buffer containing 10 mM hydroxyethylpi-
perazine ethane sulfonic acid (HEPES)eKOH, pH 7.9, 10 mM KCl, 1.5 mM
MgCl2, 0.5 mM dithiotheritol (DTT), 1 mM PMSF, 1 mM Na3VO4 and 10 mg/mlA
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Fig. 1. HDAC inhibitors TSA and BA prevent IL-1-induced NO and PGE
100 pg/ml IL-1 in the absence or presence of increasing concentrations of
for NO (A) and PGE2 (B) release. Results are expressed as percentage of
from four independent experiments. *P< 0.05 coof aprotinin, leupeptin, and pepstatin. The cells were allowed to swell on ice
and the nuclei were recovered by brief centrifugation. The pellets were resus-
pended in high salt buffer containing 20 mM HEPES, pH 7.9, 420 mM NaCl,
1.2 mM MgCl2, 0.5 mM DTT, 0.2 mM ethylenediaminetetraacetic acid (EDTA),
25% glycerol, 0.5 mM PMSF, 1 mM Na3VO4 and 10 mg/ml of aprotinin, leupep-
tin, and pepstatin, followed by incubation on ice for 20 min. The nuclear extracts
were recovered by centrifugation and protein concentrationwas determined us-
ing theBradfordmethod (Bio-Rad). A synthetic double-strandedoligonucleotide
containing the kBconsensus sequence 50-AGTTGAGGGGACTTTCCCAGGC-
30 was end-labeled by T4 polynucleotide kinase in the presence of [g-32P]
adenosine triphosphate (ATP). The mutant competitor oligonucleotide had the
following sequence with a 1 bp substitution (underlined): 50-AGTTGAGGC-
GACTTTCCCAGGC-30. The binding buffer consisted of 10 mM TriseHCl, pH
7.5, 50 mM NaCl, 0.5 mM DTT, 0.5 mM EDTA, 1 mM MgCl2, 4% glycerol and
2.5 mg poly (dIedC).Binding reactionswere conductedwith 5 mgnuclear extract
and100,000 cpm32[P]-labeledoligonucleotideprobeat22Cfor20 min inaﬁnal
volume of 10 ml. In supershift assays, the antibody to p65 (1 mg/reaction) was in-
cubated with the reaction mixture for 1 h at 4C before the addition of 32[P]-la-
beled oligonucleotide. In cold competition assays, 50-fold molar excess of
cold wild-type or mutant oligonucleotide was used. Binding complexes were re-
solved on non-denaturating 6% polyacrylamide gel electrophoresis in Trise-
borate buffer system, after which the gels were ﬁxed, dried, and subjected to
autoradiography.STATISTICAL ANALYSISData are expressed as the mean S.E.M. Statistical signiﬁcance was as-
sessed by the two-tailed Student’s t test. P values less than 0.05 were con-
sidered statistically signiﬁcant.ResultsTSA AND BA ATTENUATE IL-1-INDUCED NO AND PGE2
PRODUCTION IN HUMAN CHONDROCYTESChondrocytes were stimulated with 100 pg/ml IL-1 in the
absence or presence of increasing concentrations of two
HDAC inhibitors, TSA and BA, and the production of NO
was evaluated using Griess reagent. As shown in Fig. 1(A),
treatment with either TSA or BA suppressed IL-1-induced
NO production in a dose-dependent manner. Similarly, the
production of PGE2 was dose-dependently suppressed in
the presence of each HDAC inhibitor [Fig. 1(B)]. In another
set of experiments, we found that TSA and BA also dose-
dependently inhibited IL-1-inducedNOand PGE2 production
in normal chondrocytes, (n = 3, data not shown). The ob-
served inhibition was not a result of reduced cell viability as
conﬁrmed by the methyl thiazolyl tetrazolium (MTT) assay
(data not shown).B
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Fig. 2. TSA and BA suppress TNF-a and IL-17-induced iNOS and COX-2 protein expression. Chondrocytes were treated with TNF-a (1 ng/ml)
or IL-17 (100 ng/ml) in the absence or presence of TSA (250 ng/ml) or BA (10 mM) for 24 h. Culture media were collected and analyzed for the
production of NO (A) and PGE2 (B). Results are expressed as mean S.E.M. of three independent experiments. *P< 0.05 compared with cells
treated with TNF-a or IL-17 alone.
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PRODUCTIONThe pro-inﬂammatory cytokines TNF-a and IL-17 also
contribute to the pathogenesis of OA and are potent in-
ducers of NO and PGE2 production
1e3. Therefore, we ex-
amined whether HDAC inhibition could also attenuate
TNF-a and IL-17-induced NO and PGE2 production. As
shown in Fig. 2, stimulation of chondrocytes with TNF-a or
IL-17 dramatically increased the production of NO and
PGE2. Interestingly, the induction of NO and PGE2 produc-
tion by TNF-a or IL-17 was almost completely abolished af-
ter treatment with TSA or BA. These data suggest that the
suppressive effect of HDAC inhibitors was not speciﬁc to
IL-1, and that HDAC inhibitors might target common path-
ways implicated in NO and PGE2 production.TSA AND BA DECREASE IL-1-INDUCED iNOS AND COX-2
EXPRESSION IN CHONDROCYTESTo determine whether the inhibition of IL-1-induced NO
and PGE2 production is due to reduced iNOS, and COX-2
protein expression, the effects of HDAC inhibitors on the ex-
pression of both proteins were analyzed by WesternA B
iNOS
β-actin
COX-2
COX-1
IL-1 - + + + + +
TSA (ng/ml) 0 0 10 25 100 250
Fig. 3. TSA and BA decrease IL-1-induced iNOS and COX-2 protein ex
absence or presence of increasing concentrations of TSA (A) or BA (B
COX-2 protein expression by Western blotting. In the lower panels the b
COX-1 antibodies. The blots are representative of similarblotting. Under basal conditions, iNOS and COX-2 proteins
were undetectable and treatment with IL-1 resulted in
a strong induction of both protein expressions (Fig. 3). Con-
sistent with their effects on NO and PGE2 production,
HDAC inhibitors prevented the induction of iNOS and
COX-2 protein expression by IL-1, in a concentration-de-
pendent manner (Fig. 3). The levels of b-actin and COX-1
were not inﬂuenced by IL-1 alone or in combination with
each HDAC inhibitors (Fig. 3). IL-1-induced iNOS and
COX-2 protein expression was also inhibited by TSA and
BA in normal chondrocytes (n¼ 3, data not shown). As ex-
pected, the induction of iNOS and COX-2 proteins by TNF-
a or IL-17 was also suppressed by each HDAC inhibitor
(Fig. 4).
Next, we used real-time PCR to determine whether
HDAC inhibitors modulate iNOS and COX-2 mRNAs’ induc-
tion. The relative expression level of each gene mRNA was
plotted as fold changes over untreated control cells.
GAPDH gene expression was used for normalization. As
expected, IL-1 induced a marked increase of both iNOS
and COX-2 mRNA levels (Fig. 5). Treatment with either
TSA or BA dose-dependently suppressed the induction of
iNOS and COX-2 mRNA expression (Fig. 5), suggesting
that HDAC inhibitors exert their effects at the transcriptionaliNOS
β-actin
COX-2
COX-1
IL-1 - + + + + +
BA (mM) 0 0 0.5 1 5 10
pression. Chondrocytes were stimulated with 100 pg/ml IL-1 in the
) for 24 h. Cell lysates were prepared and analyzed for iNOS and
lots were stripped and re-probed with speciﬁc anti-b-actin or anti-
results obtained from four independent experiments.
A B
iNOS COX-2
COX-1β-actin
TNF-α - + + + - - -
IL-17 - - - - + + +
TSA - - + - - + -
BA - - - + - - +
TNF-α - + + + - - -
IL-17 - - - - + + +
TSA - - + - - + -
BA - - - + - - +
Fig. 4. TSA and BA suppress TNF-a and IL-17-induced iNOS and COX-2 protein expression. Chondrocytes were treated with TNF-a (1 ng/ml)
or IL-17 (100 ng/ml) in the absence or presence of TSA (250 ng/ml) or BA (10 mM) for 24 h. Cell lysates were prepared and analyzed for iNOS
and COX-2 protein expression by Western blotting. In the lower panels, the blots were stripped and re-probed with speciﬁc anti-b-actin or anti-
COX-1 antibodies. The blots are representative of similar results obtained from three independent experiments.
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cytes (n¼ 3, data not shown).TSA AND BA PREVENT IL-1-INDUCED PROTEOGLYCAN
DEGRADATION IN CARTILAGE EXPLANTSTo investigate the effect of HDAC inhibitors on IL-1-
induced proteoglycan degradation, cartilage explants were
incubated in DMEM with 10% FBS for 48 h and then trans-
ferred to medium containing 0.5% FBS and re-incubated for
an additional 48 h. Thereafter, the explants were stimulated
with IL-1 in the absence or presence of increasing concen-
trations of TSA or BA for 72 h, and GAG release into the su-
pernatants was determined37. As shown in Fig. 6, IL-1-
induced GAG release was inhibited in a dose-dependent
manner by either TSA or BA.TSA AND BA DO NOT IMPAIR NF-kB-BINDING TO THE iNOS
AND COX-2 PROMOTERSThe transcription factor NF-kB, mainly composed of p50
and p65 dimers, plays a pivotal role in mediating the effects
of IL-1 in chondrocytes39,40. Therefore, we performed
EMSA to determine whether HDAC inhibitors modulate IL-
1 effects by interfering with the DNA-binding activity of
NF-kB. Nuclear extracts from chondrocytes treated with0
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Fig. 5. TSA and BA decrease IL-1-induced iNOS and COX-2 mRNA exp
absence or presence of increasing concentrations of TSA or BA for 6 h
COX-2 mRNAs were quantiﬁed using real-time PCR. GAPDH gene expre
fold changes considering one as the value of untreated cells. All exper
template RNA were included in each experiment. The results are expre
compared with cells treated wIL-1 alone, or in combination with increasing concentrations
of HDAC inhibitors for 1 h, were used for these assays. As
shown in Fig. 7, IL-1 treatment induced a prominent in-
crease in the DNA-binding activity of NF-kB. Interestingly,
treatment with each HDAC inhibitor did not decrease the
DNA-binding activity of NF-kB at any concentration point.
The speciﬁcity of DNA-binding was conﬁrmed using unla-
beled wild-type and mutant oligonucleotides. The speciﬁcity
was further evidenced using supershift assays and a spe-
ciﬁc anti-p65 antibody. Together these data suggest that
HDAC inhibitors modulate IL-1 effects in chondrocytes with-
out interfering with the DNA-binding activity of NF-kB.Discussion
In the present study we demonstrated that inhibition of
HDACs by two structurally unrelated HDAC inhibitors,
TSA and BA, results in a dose-dependent suppression of
IL-1-induced NO and PGE2 production. The inhibition of
NO and PGE2 production was concomitant with the sup-
pression of iNOS and COX-2 expression at both the protein
and mRNA levels. We also showed that this inhibition is not
associated with changes in NF-kB DNA-binding activity.
The effects of HDAC inhibition on the production of NO
and the expression of iNOS have been examined in a few
recent studies. Yu et al. demonstrated that TSA inhibited0
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Fig. 6. TSA and BA suppress IL-1-induced cartilage proteoglycan
degradation. Cartilage explants were stimulated with 1 ng/ml IL-1
in the absence or presence of increasing concentrations of TSA
or BA for 72 h. Proteoglycan degradation was assessed by assay-
ing aliquots of culture media for GAG release. Results are ex-
pressed as mg GAG/mg cartilage and are the mean S.E.M. from
four independent experiments. *P < 0.05 compared with cells
treated with IL-1 alone.
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cells and RAW 264.7 cells41. Leoni et al.29 showed that an-
other HDAC inhibitor, suberoylanilide hydroxamic acid
(SAHA), dose-dependently attenuated NO release from
mouse peritoneal macrophages stimulated by the combina-
tion of TNF-a and IFN-g. Similarly, Larsen et al.42 found that
TSA and SAHA prevented the production of NO and the ex-
pression of iNOS in the b-cell line INS-1 and in intact ratBA
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TSA (ng/ml) - - 10 25 50 250 - - -
Competitor - - - - - - wt mut -
Antibody - - - - - - - - p65
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Fig. 7. Effect of TSA and BA on DNA-binding activity of NF-kB. Conﬂuen
presence of increasing concentrations of TSA (A) or BA (B) for 1 h. Nucle
nucleotide containing the NF-kB sequence. Speciﬁcity of binding was co
oligonucleotides. The supershifted (SS) band is indicated. The autoradio
independent expislets treated with IL-1þ IFN-g42 On the other hand, TSA
and SAHA have been shown to enhance LPS-induced pro-
duction of NO in microglial cells43, and butyrate was re-
ported to increase the expression of iNOS and the
production of NO in response to treatment with
LPSþ IFN-g in intestinal epithelial cells44. The reasons for
these discrepancies are unclear but may be attributable to
several factors including cell type and stimulation condi-
tions. We also demonstrated that TSA and BA prevented
IL-1-induced PGE2 release in chondrocytes. Furthermore,
TSA and BA suppressed IL-1-induced COX-2 expression
at the mRNA and protein levels. These ﬁndings are in
agreement with previous studies showing that HDAC inhib-
itors prevented the induction of PGE2 production and COX-
2 expression in several cell types45,46.
Pro-inﬂammatory cytokines TNF-a and IL-17 are also be-
lieved to contribute to the pathogenesis of OA and are
strong inducers of NO and PGE2 synthesis in chondrocy-
tes1e3. Interestingly, HDAC inhibitors blocked the produc-
tion of NO and PGE2 in chondrocytes treated with either
TNF-a or IL-17. Thus, the suppression of NO and PGE2
synthesis by HDAC inhibitors is not speciﬁc to IL-1 and is
independent of the nature of the stimulus that triggers NO
and PGE2 production.
Several studies have demonstrated that HDAC inhibitors
suppress the production of a number of pro-inﬂammatory
cytokines in vitro and in vivo. For example, treatment with
SAHA or ITF2357 decreased the release of IL-1, IL-12,
TNF-a and IFN-g from LPS-stimulated human peripheral
blood mononuclear cells29,30. TSA treatment was also re-
ported to prevent the expression of IL-8 in Caco-2 cells47
and of IL-12 in lung epithelial cells stimulated with LPS48.
In vivo, SAHA dose-dependently reduced the circulating
levels of the pro-inﬂammatory cytokines TNF-a, IL-1,
and IL-6 in an endotoxemia model29. In addition to their
anti-inﬂammatory effects, HDAC inhibitors displayIL-1 - + + + + + + + +
BA (mM) - - 0.5 5 10 - - -
Competitor - - - - - - wt mut -
Antibody - - - - - - - - p65
SS
p65
Free
probe
1
t chondrocytes were treated with IL-1 (100 pg/ml) in the absence or
ar extracts were prepared and incubated with a 32[P]-labeled oligo-
nﬁrmed using 50-molar excess of wild-type and mutated unlabeled
graph shown is representative of similar results obtained from four
eriments.
1273Osteoarthritis and Cartilage Vol. 16, No. 10chondroprotective properties. Indeed, we demonstrated
here that treatment with TSA or BA prevents IL-1-induced
proteoglycan degradation in cartilage explants. Moreover,
Young et al.49 showed that HDAC inhibitors blocked the in-
duction of several enzymes responsible for cartilage degra-
dation, including MMP-1, MMP-13, a disintegrin and
metalloproteinase domain with thrombospondin motifs
(ADAMTS) -4, -5 and -9 and prevented cartilage degrada-
tion in an explant assay49. Together these data suggest
that HDAC inhibitors may prevent cartilage destruction in
arthritis. Indeed, HDAC inhibitors prevent cartilage damage
in models of adjuvant-induced arthritis50 and autoantibody-
mediated arthritis51. Protective effects of HDAC inhibitors
on cartilage were also observed in collagen-induced arthri-
tis models52.
The transcription factor NF-kB is important in the induction of
iNOS and COX-2 by pro-inﬂammatory cytokines and stimuli in
chondrocytes, and the 50-ﬂanking regions of both iNOS and
COX-2 genes contain binding sites for NF-kB39,40. In the pres-
ent study, we demonstrated that IL-1 enhances the binding ac-
tivity ofNF-kBp65. Interestingly, treatmentwith TSAor butyrate
did not affect the binding activity of NF-kB, suggesting that
HDAC inhibitors inﬂuence NF-kB-dependent gene expression
down-stream of DNA-binding in chondrocytes. These results
are in accordancewith previous reports showing that HDAC in-
hibitors did not affect the DNA-binding activity of NF-kB in IL-1-
stimulated mesangial cells41, and Caco-2 cells47, as well as in
LPS-stimulated N9 microglia cells43. In contrast, other groups
have reported that HDAC inhibitors reduced the DNA-binding
activity of NF-kB in A549 cells53 and human colon cell lines54
treated with pro-inﬂammatory cytokines. Several reasons may
explain this dichotomy including the differences in time expo-
sure to HDAC inhibitors and the model used.
There are a number of potential mechanisms by which
HDAC inhibitors could inhibit IL-1-induced iNOS and
COX-2 expression. First, HDAC inhibitors may down-regu-
late gene expression by altering local chromatin structure
secondary to increased histone acetylation. Secondly, the
suppressive effect of HDAC inhibitors could be mediated
by hyperacetylation of transcription factors or signaling mol-
ecules that participate in IL-1-induced iNOS and COX-2 ex-
pression. Finally, gene products induced by HDAC
inhibitors may also interfere with the signaling pathways in-
volved in iNOS and COX-2 expression. Regardless of the
exact mechanism by which HDAC inhibitors down-regulate
IL-1-induced NO and PGE2 production, these results are
very interesting from a pharmacological point of view since
inhibitors of PGE2 and NO production are a promising class
of compounds with therapeutic potential for OA.
In conclusion, we have shown that HDAC inhibitors sup-
press IL-1-induced NO and PGE2 production, iNOS and
COX-2 expression as well as proteoglycan degradation.
The mechanism by which HDAC inhibitors attenuate IL-1-
effects is independent of the DNA-binding activity of the
transcription factor NF-kB. These data also suggest that
HDAC inhibitors represent a promising new class of com-
pounds in the treatment of OA.
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